In Depth Research on US Transdermal Patch Market & Clinical Trial Insight

“US Transdermal Patch Market & Clinical Trial Insight” Report Highlights:

* US Transdermal Patch Market Overview
* Generic & Branded Transdermal Patches
* US Transdermal Patch Market: Value Chain Analysis
* US Transdermal Patch Contract Manufacturing Organization
* US Transdermal Patch Clinical Pipeline Insight by Company, Indication & Phase
* US Transdermal Patch Clinical Pipeline: 55 Patches
* Majority Patches in Preclinical Phase: 27 Patches
* Marketed Transdermal Patch Clinical Insight by Company & Indication
* Marketed Transdermal Patches in US: 33 Patches

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-US-Transdermal-Patch-Market-&-Clinical-Trial-Insight.php

Table of Contents

1. Introduction to Transdermal Patch

2. Types of Transdermal Patches
2.1 Single/ Multiple-Layer Drug-in-Adhesive
2.2 Reservoir Transdermal Patches
2.3 Matrix Based Transdermal Patches
2.4 Vapor Patch
2.5 Active and Passive Patch

3. Mechanism of Transdermal Patch Drug Delivery

4. Advantages of Transdermal Patch

5. US Transdermal Patch Market Overview
5.1 Current Market Scenario
5.2 Transdermal Patch Clinical Pipeline Overview

6. Generic & Branded Transdermal Patches

7. US Transdermal Patch Market: Value Chain Analysis
7.1 Research & Development
7.2 Manufacturing
7.3 Marketing & Distribution
7.4 Price to End User

8. US Transdermal Patch Contract Manufacturing Organization (CMO)

9. US Transdermal Patch Market Growth Frontiers
9.1 Parkinson’s Disease Transdermal Patch
9.2 Alzheimer's Disease Transdermal Patch
9.3 Female Contraceptive Transdermal Patch
9.4 Nicotine Replacement Therapy Transdermal Patch
9.5 Insulin Transdermal Patch
9.6 Vaccine Transdermal Patch

10. US Transdermal Patch Market Landscape
10.1 Favorable Market Parameters
10.2 Commercialization Challenges

11. US Transdermal Patch Market Future Prospects

12. US Transdermal Patch Clinical Pipeline Insight by Company,Indication & Phase
12.1 Research
12.2 Preclinical
12.3 Phase-I
12.4 Phase-I/II
12.5 Phase-II
12.6 Phase-III
12.7 Preregistration
12.8 Registered

13. Marketed Transdermal Patch Clinical Insight by Company & Indication

14. Discontinued & Suspended Transdermal Patch Clinical Insight by Company, Indication & Phase
14.1 No Development Reported
14.2 Discontinued
14.3 Market Withdrawal
14.4 Suspended

15. Competitive Landscape
15.1 3M Pharmaceuticals
15.2 Acrux
15.3 Agile Therapeutics
15.4 Allergan
15.5 ANI Pharmaceuticals
15.6 Antares Pharma
15.7 Bayer HealthCare Pharmaceuticals
15.8 Corium International
15.9 Chase Pharmaceuticals
15.10 DURECT Corporation
15.11 Endo Pharmaceuticals
15.12 Fempharm
15.13 Hisamitsu Pharmaceutical
15.14 Immune Pharmaceuticals
15.15 Imprimis Pharmaceuticals
15.16 Ipsen Bioscience
15.17 Johnson & Johnson
15.18 LaSalle Laboratories
15.19 Lavipharm-increase
15.20 MINRAD International
15.21 NeurogesX
15.22 Noven Pharmaceuticals
15.23 NuPathe
15.24 Nuvo Research
15.25 Novartis
15.26 Pain Therapeutics
15.27 ProStrakan
15.28 Purdue Pharma
15.29 Sanofi
15.30 Scilex Pharmaceuticals
15.31 Senju Pharmaceutical
15.32 Somerset Pharmaceuticals
15.33 Teikoku Seiyaku
15.34 Therapeutic Discovery Corporation
15.35 Transdermal Delivery Solutions Corp
15.36 UCB-full form
15.37 Xel Pharmaceuticals
15.38 Zosano Pharma

Figure 1-1: Steps Involved in Transdermal Permeation
Figure 1-2: Ideal Properties of Transdermal Patch
Figure 2-1: Types of Commercially Available Transdermal Patch
Figure 3-1: Properties of Transdermal Therapeutics
Figure 3-2: Components of Transdermal Patch
Figure 3-3: Types of Permeation Enhancers
Figure 3-4: Schematic Representation of Iontophoresis
Figure 3-5: Mechanism of Scopolamine Transdermal Patch
Figure 3-6: Mechanism of Nicotine Transdermal Patch
Figure 3-7: Mechanism of Female Contraceptive Transdermal Patch
Figure 4-1: Issues with Traditional Drug Delivery Methods
Figure 4-2: Advantages of Transdermal Patch
Figure 4-3: Consistent Drug Supply by Transdermal Patch
Figure 5-1: Advantages of Transdermal Patches
Figure 5-2: Disadvantages of Transdermal Patches
Figure 5-3: US - Major Reasons Behind Growth of Transdermal Patches
Figure 5-4: US - Estimated Prescription Drug Spending (USD Billion), 2015-2020
Figure 5-5: US- Transdermal Drug Delivery System Market (US$ Billion), 2015-2020
Figure 5-6: US - Estimated Prescription Transdermal Patch Market by Volume (%), 2015 & 2020
Figure 5-7: US - Estimated Market Size of Prescription vs. Over-The-Counter Transdermal Patches (US$ Billion), 2015
Figure 5-8: US - Estimated Market Size of Prescription vs. Over-The-Counter Transdermal Patches (US$ Billion), 2020
Figure 5-9: US Transdermal Patch Pipeline by Phase (%)
Figure 5-10: US Transdermal Patch Pipeline by Phase (Number)
Figure 5-11: US - No Development Reported in Transdermal Patch Pipeline by Phase (%)
Figure 5-12: US -No Development Reported in Transdermal Patch Pipeline by Phase (%)
Figure 5-13: US -Discontinued Transdermal Patch Pipeline by Phase (%)
Figure 5-14: US -Discontinued Transdermal Patch Pipeline by Phase (Number)
Figure 6-1: Requirement in Generic Transdermal Patches
Figure 6-2: Reservations for Generic Transdermal Patches
Figure 6-3: US - Estimated Cost Comparison of Branded vs. Generic Contraceptive Patch
Figure 6-4: US - Estimated Cost Comparison of Cigarettes, Generic & Branded Nicotine Patches
Figure 7-1: Basic Features of Transdermal Patch Value Chain
Figure 7-2: Steps Involved in Transdermal Patch Manufacturing
Figure 8-1: Stages of Transdermal Patch Development
Figure 8-2: Advantages of Using Contract Manufacturing Organization for Transdermal Drug Delivery System
Figure 8-3: Requirements from Contract Manufacturing Organization for Transdermal Drug Delivery System
Figure 9-1: Potential Market Segments of Transdermal Drug Delivery Systems
Figure 9-2: US - Susceptibility of Parkinson Disease among Males and Females
Figure 9-3: US - Estimated Increase in Parkinson’s Disease Incidences
Figure 9-4: US - Estimated Financial Impact of Parkinson’s Disease on Economy (US$ Billion)
Figure 9-5: US - Parkinson’s Disease Incidences, 2015-2020
Figure 9-6: US - Estimated Sales of Neupro Patch, 2104-2020
Figure 9-7: US - Estimated Worldwide Sales of Neupro, 2014 & 2015
Figure 9-8: US - Male & Female Suffering from Alzheimer’s Disease (Million), 2015
Figure 9-9: US - Shares of Male & Female Suffering from Alzheimer’s Disease (%), 2015
Figure 9-10: US - Percentage of Elderly People Suffering from Alzheimer’s Disease, 2015
Figure 9-11: US - Estimated Increase in Alzheimer’s Incidences, 2015, 2025 & 2050
Figure 9-12: US - Estimated Incidences of Alzheimer’s Disease, 2015-2020
Figure 9-13: US - Exelon Patch Sales for Alzheimer s Disease, 2013 & 2014
Figure 9-14: Requirements of Female Contraceptive Transdermal Drug Delivery Systems
Figure 9-15: Benefits of Female Contraceptive Transdermal Drug Delivery System
Figure 9-16: US - Expected Revenues Generated by Xulane Patch (US$ Million), 2015-2020
Figure 9-17: US - Decrease in Number of Smokers due to Nicotine Patch, 2005 & 2013
Figure 9-18: Factors Responsible for Increased Consumption of Nicotine Patches
Figure 9-19: Rank of US among Different Diabetes Prone Countries
Figure 9-20: US - Estimated Increase in Diabetes Incidences, 2015-2020
Figure 9-21: Benefits of Insulin Transdermal Patch
Figure 9-22: Drawback of Insulin Transdermal Patch
Figure 9-23: Benefits of Vaccine Transdermal Patch
Figure 9-24: Drawbacks of Vaccine Transdermal Patch
Figure 9-25: US - Estimated HIV Incidences, 2015-2020
Figure 10-1: Transdermal Patch Market Favorable Factors
Figure 10-2: Transdermal Patch Market Commercialization Challenges
Figure 15-1: Acrux Clinical Pipeline
Figure 15-2: Agile Therapeutics Clinical Pipeline
Figure 15-3: Antares Pharma Clinical Pipeline
Figure 15-4: Corium International Clinical Pipeline
Figure 15-5: Durect Corporation Clinical Pipeline
Figure 15-6: Endo Pharmaceuticals Clinical Pipeline
Figure 15-7: Immune Pharmaceuticals Clinical Pipeline
Figure 15-8: Novartis Clinical Pipeline
Figure 15-9: Senju Pharmaceuticals Clinical Pipeline
Figure 15-10: Xel Pharamaceuticals Clinical Pipeline
Figure 15-11: Zosano Pharma Clinical Pipeline

List of Tables

Table 3-1: Transdermal Patches for Various Disease Indications
Table 5-1: Features Required in Transdermal Patches
Table 5-2: US - Different Transdermal Drug Delivery Systems Available in Market
Table 6-1: Similarities & Difference Between Generic & Branded Transdermal Patches
Table 6-2: US - Some Generic Transdermal Patches Available in Market
Table 7-1: Breakdown of Transdermal Patch Value Chain Analysis
Table 9-1: US - Estimated Adoption Rates for Parkinson s Disease Transdermal Patches , 2015-2020
Table 9-2: Description of Neupro Patch for Parkinson’s Disease
Table 9-3: US - Estimated Adoption Rates for Transdermal Drug Delivery Systems for Alzheimer s Disease, 2015-2020
Table 9-4: Transdermal Patches for Alzheimer’s Disease
Table 9-5: Description of Ortho Evra Contraceptive Patch
Table 9-6: Difference Between Generic & Branded Transdermal Contraceptive Products
Table 9-7: US-Estimated Adoption Rates for Transdermal Drug Delivery Systems for Diabetes Mellitus, 2015-2020
Table 9-8: US-Estimated Adoption rates for Transdermal Drug Delivery Systems for HIV, 2015-2020
Table 15-1: Pain Therapeutics Clinical Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
India
+91-11-47067990

This release was published on openPR.